Your browser doesn't support javascript.
loading
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.
Basci, Semih; Ata, Naim; Altuntas, Fevzi; Yigenoglu, Tugçe Nur; Dal, Mehmet Sinan; Korkmaz, Serdal; Namdaroglu, Sinem; Bastürk, Abdülkadir; Hacibekiroglu, Tuba; Dogu, Mehmet Hilmi; Berber, Ilhami; Dal, Kürsat; Erkurt, Mehmet Ali; Turgut, Burhan; Çaglayan, Murat; Ayvali, Mustafa Okan; Çelik, Osman; Ülgü, Mustafa Mahir; Birinci, Suayip.
Afiliação
  • Basci S; Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Ata N; Department of Strategy Development, Ministry of Health, Republic of Turkey, Ankara, Turkey.
  • Altuntas F; Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Yigenoglu TN; Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Dal MS; Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Korkmaz S; Department of Hematology, Kayseri City Hospital, University of Health Sciences, Kayseri, Turkey.
  • Namdaroglu S; Department of Hematology, Bozyaka Training and Research Hospital, University of Health Sciences, Izmir, Turkey.
  • Bastürk A; Division of Hematology, Department of Internal Medicine, School of Medicine, Selçuk University, Konya, Turkey.
  • Hacibekiroglu T; Division of Hematology, Department of Internal Medicine, School of Medicine, Sakarya University, Sakarya, Turkey.
  • Dogu MH; Department of Hematology, Istanbul Training and Research Hospital, Istanbul, Turkey.
  • Berber I; Division of Hematology, Department of Internal Medicine, School of Medicine, Inönü University, Malatya, Turkey.
  • Dal K; Department of Internal Medicine, Keçiören Training and Research Hospital, Ankara, Turkey.
  • Erkurt MA; Division of Hematology, Department of Internal Medicine, School of Medicine, Inönü University, Malatya, Turkey.
  • Turgut B; Division of Hematology, Department of Internal Medicine, School of Medicine, Namik Kemal University, Tekirdag, Turkey.
  • Çaglayan M; Ankara Provincial Health Directorate, Ministry of Health, Republic of Turkey, Ankara, Turkey.
  • Ayvali MO; General Directorate of Health Information Systems, Ministry of Health, Republic of Turkey, Ankara, Turkey.
  • Çelik O; Public Hospitals General Directorate, Ministry of Health, Republic of Turkey, Ankara, Turkey.
  • Ülgü MM; General Directorate of Health Information Systems, Ministry of Health, Republic of Turkey, Ankara, Turkey.
  • Birinci S; Deputy Minister of Health, Republic of Turkey, Ankara, Turkey.
J Oncol Pharm Pract ; 26(7): 1676-1682, 2020 Oct.
Article em En | MEDLINE | ID: mdl-32854573
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Leucemia Mielogênica Crônica BCR-ABL Positiva / Infecções por Coronavirus / Pandemias / Mesilato de Imatinib / Betacoronavirus / Tempo de Internação Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Leucemia Mielogênica Crônica BCR-ABL Positiva / Infecções por Coronavirus / Pandemias / Mesilato de Imatinib / Betacoronavirus / Tempo de Internação Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2020 Tipo de documento: Article